Study Title
ACNS1821: A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Protocol ID
ACNS1821
Disease (Sub Disease)
Anaplastic Astrocytoma
Anaplastic Astrocytoma, Not Otherwise Specified
Diffuse Intrinsic Pontine Glioma
Diffuse Midline Glioma, H3 K27M-Mutant
Glioblastoma
Glioblastoma, Not Otherwise Specified
Malignant Glioma
Anaplastic Astrocytoma, Not Otherwise Specified
Diffuse Intrinsic Pontine Glioma
Diffuse Midline Glioma, H3 K27M-Mutant
Glioblastoma
Glioblastoma, Not Otherwise Specified
Malignant Glioma
Diagnosis Stage
Newly diagnosed
Location
QLD, VIC, NZ
Sponsor
National Cancer Institute (NCI)
Links
Trial Status
Open
Sites
Queensland Children's Hospital
Christchurch Hospital
The Royal Children's Hospital
Starship Hospital
Christchurch Hospital
The Royal Children's Hospital
Starship Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
12 Months to 21 Years
International registry ID's
NCT05099003
| Study Title | ACNS1821: A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) |
|---|---|
| Protocol ID | ACNS1821 |
| Disease (Sub Disease) | Anaplastic Astrocytoma Anaplastic Astrocytoma, Not Otherwise Specified Diffuse Intrinsic Pontine Glioma Diffuse Midline Glioma, H3 K27M-Mutant Glioblastoma Glioblastoma, Not Otherwise Specified Malignant Glioma |
| Diagnosis Stage | Newly diagnosed |
| Location | QLD / VIC / NZ |
| Sponsor | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT05099003 |
| Trial Status | Open |
| Trial Open Date | 05/05/2022 |
| Sites | Queensland Children's Hospital / Christchurch Hospital/ The Royal Children's Hospital/ Starship Hospital |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | 12 Months to 21 Years |
| International registry ID's | NCT05099003 |